Examining the Growing Challenge of Extractables and Leachables - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Examining the Growing Challenge of Extractables and Leachables
Experts share insight into extractables and leachables testing, including high-risk products, analytical testing, and regulatory requirements from FDA and EMA.

Pharmaceutical Technology
Volume 36, Issue 11, pp. 38-41

Rushing (ABC Laboratories): Regulatory expectations continue to increase. Drug–device combinations that historically garnered little regulatory attention in regards to E&L are now receiving more in-depth scrutiny. Over the past couple of years, several oral and dermal solution formulations have received either deficiency letters or specific information requests from FDA asking for in-depth E&L information for drug products. It is likely that this trend will soon spread to affect products that were traditionally considered to be at a lower risk of E&Ls as emphasis in this area continues.

PharmTech: How do regulatory expectations for E&L testing and toxicological assessments vary between EMA and FDA?

Christiaens (Toxikon Europe): The regulatory expectations in Europe (EMA) and the US (FDA) are very similar. However, in my experience, variability between different reviewers within the same authority regarding what level of documentation they expect is higher than the difference in official standpoints concerning what documentation to submit with regard to the qualification of the pharmaceutical packaging materials between FDA and EMA.

Feilden (Smithers Rapra): The significant differences between the two regulatory authorities are in the amount of information supplied on how to conduct testing. FDA points to the Product Quality Research Institute (PQRI) recommendations, but the EMA guidance is a lot shorter and doesn't go into specifics. Generally, PQRI recommendations tend to be followed because they are more stringent than EMA. PQRI has a level of 0.15 g/day for identifying species whereas the EMA has 1.5 g/day. There doesn't appear to be any difference between toxicological assessments for either regulators, but a toxicologist would be able to confirm this.

Kesselring (EAG Life Sciences): Although it is difficult to predict how developing regulatory requirements may contrast, I have found the current expectations for E&L testing between EMA and FDA to be more similar than different. I believe the background that has allowed this to occur is that the development of industry E&L study concepts has coincided closely with the development of the International Conference on Harmonization. It is also notable that the E&L industry driving force of the PQRI has been a multinational effort both in its recommendation development, as well as its promotion of the developed concepts.

Killian (EMD Millipore): There are some differences between EMA and FDA. EMA is quicker to incorporate ICH documents and is more willing to put out guidance documents (e.g., the 2009 CHMP Guideline on the Limits of Genotoxic Impurities). FDA is more noncommittal, leaving it up to the drug company to demonstrate that E&Ls do not pose a risk to the patient.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here